IBDEI15G ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18661,2)
 ;;=^5003026
 ;;^UTILITY(U,$J,358.3,18662,0)
 ;;=E11.9^^64^834^11
 ;;^UTILITY(U,$J,358.3,18662,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18662,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,18662,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,18662,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,18663,0)
 ;;=E10.9^^64^834^1
 ;;^UTILITY(U,$J,358.3,18663,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18663,1,3,0)
 ;;=3^DM Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,18663,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,18663,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,18664,0)
 ;;=Z79.4^^64^834^14
 ;;^UTILITY(U,$J,358.3,18664,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18664,1,3,0)
 ;;=3^Long Term Use of Insulin
 ;;^UTILITY(U,$J,358.3,18664,1,4,0)
 ;;=4^Z79.4
 ;;^UTILITY(U,$J,358.3,18664,2)
 ;;=^5063334
 ;;^UTILITY(U,$J,358.3,18665,0)
 ;;=E11.22^^64^834^3
 ;;^UTILITY(U,$J,358.3,18665,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18665,1,3,0)
 ;;=3^DM Type 2 w/ CKD
 ;;^UTILITY(U,$J,358.3,18665,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,18665,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,18666,0)
 ;;=E11.42^^64^834^10
 ;;^UTILITY(U,$J,358.3,18666,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18666,1,3,0)
 ;;=3^DM Type 2 w/ Peripheral Neuropathy
 ;;^UTILITY(U,$J,358.3,18666,1,4,0)
 ;;=4^E11.42
 ;;^UTILITY(U,$J,358.3,18666,2)
 ;;=^5002646
 ;;^UTILITY(U,$J,358.3,18667,0)
 ;;=E11.43^^64^834^2
 ;;^UTILITY(U,$J,358.3,18667,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18667,1,3,0)
 ;;=3^DM Type 2 w/ Autonomic Neuropathy
 ;;^UTILITY(U,$J,358.3,18667,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,18667,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,18668,0)
 ;;=E11.51^^64^834^9
 ;;^UTILITY(U,$J,358.3,18668,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18668,1,3,0)
 ;;=3^DM Type 2 w/ Peripheral Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,18668,1,4,0)
 ;;=4^E11.51
 ;;^UTILITY(U,$J,358.3,18668,2)
 ;;=^5002650
 ;;^UTILITY(U,$J,358.3,18669,0)
 ;;=E11.52^^64^834^8
 ;;^UTILITY(U,$J,358.3,18669,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18669,1,3,0)
 ;;=3^DM Type 2 w/ Peripheral Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,18669,1,4,0)
 ;;=4^E11.52
 ;;^UTILITY(U,$J,358.3,18669,2)
 ;;=^5002651
 ;;^UTILITY(U,$J,358.3,18670,0)
 ;;=E11.621^^64^834^4
 ;;^UTILITY(U,$J,358.3,18670,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18670,1,3,0)
 ;;=3^DM Type 2 w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,18670,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,18670,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,18671,0)
 ;;=E11.649^^64^834^6
 ;;^UTILITY(U,$J,358.3,18671,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18671,1,3,0)
 ;;=3^DM Type 2 w/ Hypoglycemia w/o Coma
 ;;^UTILITY(U,$J,358.3,18671,1,4,0)
 ;;=4^E11.649
 ;;^UTILITY(U,$J,358.3,18671,2)
 ;;=^5002662
 ;;^UTILITY(U,$J,358.3,18672,0)
 ;;=E11.65^^64^834^5
 ;;^UTILITY(U,$J,358.3,18672,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18672,1,3,0)
 ;;=3^DM Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,18672,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,18672,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,18673,0)
 ;;=E11.69^^64^834^7
 ;;^UTILITY(U,$J,358.3,18673,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18673,1,3,0)
 ;;=3^DM Type 2 w/ Other Complications
 ;;^UTILITY(U,$J,358.3,18673,1,4,0)
 ;;=4^E11.69
 ;;^UTILITY(U,$J,358.3,18673,2)
 ;;=^5002664
 ;;^UTILITY(U,$J,358.3,18674,0)
 ;;=Z79.84^^64^834^13
